Effects of Atorvastatin on Dyslipidemia in Uraemic Patients on Peritoneal Dialysis

18 Aug, 10

Effects of Atorvastatin on Dyslipidemia in Uraemic Patients on Peritoneal Dialysis

Aim

To evaluate the efficacy and safety of atorvastatin, a potent cholesterol-and triglyceride-lowering agent, in peritoneal dialysis patients with dyslipidemia.

Patients

31 peritoneal dialysis patients with hypercholesterolemia (mean age 57 - 16 years; mean duration of peritoneal dialysis 27 - 17 months).

Follow-up

4 months

Treatment Regimen

Atorvastatin 10-40 mg/day

Results

Mean LDL cholesterol levels decreased significantly by 42% and 46% from 204 - 23 mg/dl to 119 - 27 mg/dl and 198 - 37 to 104 - 21 mg/dl in the primary and secondary prevention patients respectively.
Mean triglyceride levels decreased by 37% and 26% from 289 - 132 mg/dl to 186 - 92 mg/dl and 201 - 62 to 150 - 54 mg/dl in the primary and secondary prevention patients respectively.
Nineteen primary prevention and seven secondary prevention patients achieved the LDL cholesterol target. The triglyceride target was achieved by 15 of the 19 hypertriglyceridemic patients.
After 4 months, there were no changes in enzyme levels.

Conclusion

Atorvastatin is an effective and safe lipid-lowering agent for peritoneal dialysis patients with mixed dyslipidemia.

Nephrology, Dialysis, Transplantation 2000:684-8